Clarence Jones

And I'm wondering again about the importance of having this information available for parenting groups.

Yeah.

And I haven't seen anything about that.

And so perhaps you can can help help me with that in terms of presenting that information, because I think what you're saying right now, one in 28 here in Minnesota.

And I know how how behavior is one of the factors that families really, you know, they really are looking at for their children, how this might be important information for them.

But you know what?

I think, Stan, I think when a person has to affirm that or say that, that says something about them too.

They agree.

Yeah.

They want to show that their child has some value, that there's some conflict that's there, you know, and so they want people to accept that child as as, quote unquote, normal or just that.

Well, we have some difficulties, but he's really he or she is really a great child.

And I think that's part of the part of the challenge in terms of this particular child.

uh issue is that we know so little about it and we look so much at the behavior as a as a kind of like as the final piece of how we're going to evaluate that child so families want to protect that child and so i can understand that a few people would say well my child is low functioning

Because that appears to them to be a reflection on them.

So I mean, this conversation to me is so important to have so that people can really understand and become more comfortable with talking about this.

So I'm concerned, this is Clarence, I'm concerned about the whole issue around polypharmaceuticals.

I mean, here we go, we keep adding and adding and adding.

What kind of conversation should we be having

about this drug and how it might impact, as Dr. Ronald was talking about, how this might impact the real health of people, either now or in the future?

What should we be thinking about?